An update on inhibitors of human 14 kDa Type II s-PLA2 in development.
Recent progress in the development of inhibitors of human Type II s-PLA2 as potential anti-inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY-315920 (S-5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY-315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s-PLA2 that have been reported to be in late-stage development
Springer
D M
DM
Anti-infective Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, P.O. Box 5100, Wallingford, CT 06492, USA.
D000085:Acetates / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000494:pharmacology*; D015195:Drug Design; D054501:Group II Phospholipases A2; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007651:Keto Acids; D015394:Molecular Structure; D010330:Patents as Topic; D010741:Phospholipases A / Q000037:antagonists & inhibitors* / Q000737:chemistry; D054467:Phospholipases A2; D013449:Sulfonamides / Q000494:pharmacology; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000494:pharmacology
D000085:Acetates; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007211:Indoles; D007651:Keto Acids; C095801:SB 203347; D013449:Sulfonamides; C078415:13-cis-12-(3'-carboxyphenyl)retinoic acid; C117948:varespladib; D014212:Tretinoin; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2